Australia changes drug approval norms to speed up approval process

Singapore: With a view to speed up the approval process and improve access to breakthrough drugs, the Australian federal...

September 21, 2016 | Wednesday | News
Semaglutide reduces risk of cardiovascular problems among type 2 Diabetic patients

Munich: Danish Drug maker Novo Nordisk recently announced that patients treated with Semaglutide, an investigational glu...

September 19, 2016 | Monday | News
Eisai receives license for new indication for anticancer agent Kisplyx

TOKYO: Eisai Co., Ltd. announced that its European regional headquarters Eisai Europe Ltd. has received license from the...

September 15, 2016 | Thursday | News
Singapore develops new protein to alter DNA in living cells

Singapore: Researchers in Singapore have developed a new protein that can alter DNA in living cells with much higher pre...

September 14, 2016 | Wednesday | News
Glenmark receives ANDA approval for Nystatin, Triamcinolone Acetonide ointment

Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food & Drug Administrat...

August 8, 2016 | Monday | News
Novogen progresses on drugs against genetic, degenerative disorders

Singapore: Australian company Novogen, engaged in a pilot program aimed at breakthrough development of drugs to treat a ...

November 14, 2013 | Thursday | News
Glenmark develops first-of-its-kind antibody

Singapore: Glenmark Pharmaceuticals has started the discovery and initiation of IND enabling studies of a novel clinical...

February 5, 2013 | Tuesday | News
Tivozanib shows superiority over sorafenib in trial

Singapore: Investigational agent, tivozanib, has demonstrated statistically significant and clinically meaningful PFS su...

May 18, 2012 | Friday | News
Pluristem secures Japan's PMDA nod on regenerative drug trial protocol

Pluristem Therapeutics Inc., Israel's developer of placenta-based cell therapy products, has reached an agreement with J...

December 22, 2015 | Tuesday | News
Bone Medical reveals results of arthritis study

Singapore: Australia-based Bone Medical, a biopharmaceutical company focused on the development of new medicines for mus...

January 30, 2013 | Wednesday | News
FDA nod for Novartis Cushing's disease drug Signifor

Singapore: The US FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support o...

November 8, 2012 | Thursday | News
Chugai gets positive outcome from Actemra Subcutaneous Injection trials

Japanese pharmaceutical giant Chugai Pharmaceutical Co Ltd has announced that its Actemra Subcutaneous Injection (Actemr...

May 17, 2016 | Tuesday | News
Prosetta Biosciences, Takeda to co-discover drugs for neurodegenerative diseases

Prosetta Biosciences Inc. has entered into a Feasibility and First Right of Negotiation Agreement with Japan's Takeda Ph...

May 3, 2016 | Tuesday | News
FDA approves Lupin's new generic

Pharma Major Lupin announced that its US subsidiary, Gavis Pharmaceuticals LLC., (collectively Lupin) has received final...

June 23, 2016 | Thursday | News
Gout therapeutics market clocks $988.7 mn in 2011

Singapore: GlobalData's analysis shows that the global gout therapeutics market grew at a compound annual growth rate (...

May 23, 2012 | Wednesday | Analysis
Pfizer, Repligen to push spinal muscular atrophy program

Singapore: US-based Repligen has entered into an exclusive worldwide licensing agreement with Pfizer to advance Repligen...

January 7, 2013 | Monday | News
UK commits $1.6 bn to fight AIDS, TB, Malaria

Singapore: United Kingdom (UK) has committed to contrbute $1.6 billion to fight AIDS, Tuberculosis and Malaria. Ms Just...

September 24, 2013 | Tuesday | News
China firm Beigene raises $75 mn

Singapore: China based biotech firm developing targeted and immune-oncology therapeutics, BeiGene, has raised $75 millio...

November 18, 2014 | Tuesday | News

Podcast

Survey Box

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls